MBX Biosciences, Inc.
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 74.85% | 66.88% | 65.37% | 57.83% | 57.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.79% | 52.53% | 70.02% | 92.65% | 93.13% |
| Operating Income | -43.79% | -52.53% | -70.02% | -92.65% | -93.13% |
| Income Before Tax | -40.45% | -45.88% | -63.18% | -88.61% | -90.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.45% | -45.88% | -63.18% | -88.61% | -90.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.45% | -45.88% | -63.18% | -88.61% | -90.17% |
| EBIT | -43.79% | -52.53% | -70.02% | -92.65% | -93.13% |
| EBITDA | -43.94% | -52.70% | -70.13% | -92.77% | -93.30% |
| EPS Basic | 90.75% | 92.83% | 88.64% | 52.70% | 17.69% |
| Normalized Basic EPS | 90.47% | 92.77% | 88.67% | 53.66% | 19.72% |
| EPS Diluted | 90.75% | 92.83% | 88.63% | 52.70% | 17.69% |
| Normalized Diluted EPS | 90.47% | 92.77% | 88.67% | 53.66% | 19.72% |
| Average Basic Shares Outstanding | 244.64% | 1,228.68% | 2,179.01% | 1,587.68% | 940.14% |
| Average Diluted Shares Outstanding | 244.64% | 1,228.68% | 2,179.01% | 1,587.68% | 940.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |